|
|
Somalogic Inc (NASDAQ: SLGC) |
|
Price: $2.1000
$-0.10 
-4.545%
|
| Day's High:
| $2.31
| Week Perf:
| -17 %
|
| Day's Low: |
$ 1.93 |
30 Day Perf: |
-21.35 % |
| Volume (M): |
33,911 |
52 Wk High: |
$ 0.00 |
| Volume (M$): |
$ 71,212 |
52 Wk Avg: |
$0.00 |
| Open: |
$2.16 |
52 Wk Low: |
$0.00 |
|
|
| Market Capitalization (Millions $) |
393 |
| Shares
Outstanding (Millions) |
187 |
| Employees |
470 |
| Revenues (TTM) (Millions $) |
82 |
| Net Income (TTM) (Millions $) |
-130 |
| Cash Flow (TTM) (Millions $) |
-79 |
| Capital Exp. (TTM) (Millions $) |
3 |
Somalogic Inc
SomaLogic Inc. is a privately held biotechnology company located in Boulder, Colorado, specializing in the development and application of protein detection technology for the advancement of healthcare and diagnostics. The company was founded in 2000 by Larry Gold, a renowned scientist and inventor of the gold standard SELEX technology, which is used for the identification of specific protein binding molecules.
The companyes proprietary SOMAscan platform is based on a modified version of DNA aptamers, which are short single-stranded DNA molecules that bind specifically to target proteins with high affinity and selectivity. The SOMAscan assay measures the levels of over 7,000 different proteins in a single serum or plasma sample, providing a comprehensive and highly sensitive esnapshote of an individuales health status.
SomaLogic has developed strategic partnerships with multiple organizations and institutions to apply the SOMAscan technology in different settings. The company has collaborated with the National Institutes of Health (NIH) to study biomarker discovery in a wide range of diseases, including Alzheimeres disease, cancer, heart disease, infectious diseases, and metabolic disorders.
SomaLogic has also partnered with several pharmaceutical companies to assist in drug discovery and development, including Novartis, Bristol Myers Squibb, and Debiopharm Group. Through these partnerships, the SOMAscan technology has been used to identify potential targets for drug development, validate drug candidates, and assess drug efficacy and safety.
In addition to its research and development efforts, SomaLogic offers commercial services for healthcare and pharmaceutical companies, including biomarker discovery, drug development support, and clinical testing, among others.
Overall, SomaLogic is a leader in the field of protein detection and personalized medicine, providing innovative solutions for research and clinical diagnostics. As the company continues to expand and develop new applications for its platform technology, it has the potential to revolutionize the way we diagnose and treat disease.
Company Address: 2945 Wilderness Place Boulder 80301 CO
Company Phone Number: 625-9000 Stock Exchange / Ticker: NASDAQ SLGC
|
|
|
|
|
|
|
| Stock Performances by Major Competitors |
|
|
|
| Stock Market Announcement
Published Fri, Dec 22 2023 11:48 PM UTC
In an era of volatile financial markets, companies are constantly challenged to find innovative ways to maximize shareholder value. With this objective in mind, a prominent organization is urging its stockholders to vote in favor of a value maximizing transaction at an upcoming special meeting. This transformative move has the potential to reshape the company s fut...
|
| Somalogic Inc
Somalogic Inc, a prominent player in proteomics technology, recently reported its financial results for the third quarter of 2023. While the company witnessed a decrease in losses per share compared to the previous year, it also experienced a decline in revenue. This article will delve into the implications of these results and ponder how they may impact Somalogic Inc's future prospects.
Decreased Losses per Share:
Somalogic Inc demonstrated a notable improvement in its losses per share, dropping from $-0.18 to $-0.12 when compared to the same reporting period last year. This reduction indicates that the company is making progress in managing its expenses and curtailing losses. However, it is essential to evaluate whether this trend will continue and lead to sustainable profitability in the long run.
|
| Somalogic Inc
Introduction
In the financial period ending June 30, 2023, Somalogic Inc (SLGC) experienced a net loss of $0.13 per share. However, the company's revenue witnessed a significant surge of 44.712%, reaching $20.47 million compared to the same reporting period the previous year. Despite facing financial challenges, Somalogic Inc has managed to outperform its industry peers in terms of revenue growth. This article aims to analyze the company's financial performance, stockpiles, and accounts receivable, shedding light on the factors behind the industry's growth and the subsequent impact on Somalogic Inc's performance.
Financial Performance
Although Somalogic Inc incurred losses in the latest financial period, it is crucial to note that the company's revenue growth of 44.712% demonstrates a promising trajectory. Comparatively, the Medical Laboratories industry reported a revenue increase of 3.90% during the same period, indicating that Somalogic Inc has outperformed its competitors. In the previous reporting period, the company's revenue was $20.38 million, with a net loss of $0.18 per share. Therefore, despite the reduction in net losses per share, it is still crucial for Somalogic Inc to focus on improving its profitability.
|
| Somalogic Inc
19Somalogic Inc, a company operating in the Medical Laboratories industry, recently released its financial results for the 12 months ending in the first quarter of 2023. Unfortunately, the company reported a cumulative net loss of $-139 million during this period, resulting in a negative return on equity of -24.16%. Additionally, the company's ROE is below the industry average, as 21 other companies in the Medical Laboratories industry had a higher ROE.
However, there is some good news for Somalogic Inc. Their return on equity ranking has improved in the first quarter of 2023, moving from 2906 in the fourth quarter of 2022 to 2352 overall. This indicates that the company is making some progress, although there is still work to be done to improve their financial performance.
Looking more closely at the financial results, it is clear that Somalogic Inc experienced a surge in their deficit per share in the first quarter of 2023, with a deficit of $-0.18 per share compared to $-0.02 per share the previous year. This represents a significant decline and suggests that the company needs to focus on improving their profitability going forward.
In addition, Somalogic Inc also saw a decline in revenue during the first quarter of 2023, with a drop of -11.319% to $20.38 million compared to $22.98 million the previous year. However, the company was able to increase its revenue sequentially by 8.232% from $18.83 million. While this improvement is welcome, it is clear that the company needs to work on stabilizing its revenue streams to support long-term growth.
Overall, Somalogic Inc faces significant challenges as it seeks to improve its financial performance. While there are some positive signs of progress, such as the improved return on equity ranking, the company must focus on reducing their net loss, improving revenue and stabilizing their finances. The upcoming financial earnings report on August 14, 2023, will be an important indicator of the company's progress and its ability to overcome these challenges.
|
| Per Share |
Current |
| Earnings (TTM) |
-0.6 $ |
| Revenues (TTM) |
0.44 $
|
| Cash Flow (TTM) |
- |
| Cash |
2.43 $
|
| Book Value |
2.66 $
|
| Dividend (TTM) |
0 $ |
|
|
| Per Share |
|
| Earnings (TTM) |
-0.6 $
|
| Revenues (TTM) |
0.44 $ |
| Cash Flow (TTM) |
- |
| Cash |
2.43 $
|
| Book Value |
2.66 $ |
| Dividend (TTM) |
0 $ |
|
|
|
|
0.07%